Answers are grounded in this paper and cite their sources.
Primary hepatic neuroendocrine tumors (PHNETs) account for only 0.3% of all the primary neuroendocrine tumors(NETs). Since, liver is the most frequent site of metastasis of NETs from other sites in the body; a distinction between metastatic liver mass and primary NET is extremely necessary. This report describes the case of a 54-year-old male who presented with right hypochondrial pain and had a space occupying lesion in the left lobe of liver and multiple small lesions in both the lobes of liver. USG guided tru-cut biopsy showed malignant neoplasm of grade III comprising of sheets and nests of atypical plasmacytoid looking cells with brisk mitosis. Immunohistochemically, synaptophysin and cytokeratin were positive with Ki-67 index of 30%. Hormonal studies were normal; hence, a diagnosis of non-functioning PHNET was made. Patient was treated stepwise with cisplatin/etoposide based chemotherapy, Everolimus, capecitabine and temozolomide; but, all the therapies failed to produce response and ultimately, patient was put on pembrolizumab as a palliative measure. This case illustrates that PHNET should be amongst the differentials of a liver mass and a comprehensive research is needed to devise successful management strategies. • Primary hepatic neuroendocrine tumors (PHNETs) account for only 0.3% of all the primary neuroendocrine tumors(NETs). • This report describes a 54-year-old male having PHNET who was commenced on palliative pembrolizumab after chemotherapy failed. • PHNET should be amongst the differentials of a liver mass and a comprehensive research is needed to devise successful management strategies.
No takes yet. Share an insight, caveat, or question.
Mumtaz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: